Cholinesterase-inhibitoren und Alzheimer-demenz: Metaanalyse zu wirksamkeitsnachweis, ursprung und ergebnisverzerrung in publizierten studien

Translated title of the contribution: Cholinesterase inhibitors and Alzheimer's disease: Demonstrable efficacy, origin and bias of published studies

Silvia Egert, S. Wagenpfeil, H. Förstl

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background and objective: The cholinesterase-inhibitors (AChE-I) donepezil, galantamine and rivastigmine are currently used in the symptomatic treatment of patients with Alzheimer's dementia (AD) and the associated cholinergic deficits as well as those with other forms of dementia. Threee aspects were analysed: (1) data on their clinical efficacy, (2) differences between North-American and international studies, and (3) potential publication biases. Methods: Included were data from randomized, placebo-controlled, double-blind parallel group trials on more than 100 patients who had been treated for ≥12 weeks for AD, VaD, dementia with Lewy bodies, dementia with Parkinson's disease or with mild cognitive impairment. Results: These large published trials support the clinical efficacy of AChE-1 in patients with mild to moderate AD and other forms of dementia with regard to cognition and global impression, there was a trend towards greater beneficial cognitive effects in North-American studies, but this was non-significant. There was no evidence of a publication bias. Conclusions: Published data provide evidence for the clinical efficacy of donepezil, galantamine and rivastigmine in patients with mild to moderate AD. There is no indication that these results are critically influenced by the origin or a bias of the publication.

Translated title of the contributionCholinesterase inhibitors and Alzheimer's disease: Demonstrable efficacy, origin and bias of published studies
Original languageGerman
Pages (from-to)1207-1213
Number of pages7
JournalDeutsche Medizinische Wochenschrift
Volume132
Issue number22
DOIs
StatePublished - 1 Jun 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cholinesterase inhibitors and Alzheimer's disease: Demonstrable efficacy, origin and bias of published studies'. Together they form a unique fingerprint.

Cite this